Bind Therapeutics is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins. Accurins are designed to accumulate at the site of disease and provide high drug concentrations for an extended period of time to enable the potential for a single administration. Bind is developing a pipeline of novel Accurins that hold promise in oncology, inflammatory diseases, and cardiovascular disorders. Bind's lead product candidate, BIND-014, is a prostate-specific membrane antigen (PSMA) -targeted Accurin that is currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer.